These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18626947)

  • 1. The impact of war-stress on MS exacerbations.
    Goodin DS
    Ann Neurol; 2008 Aug; 64(2):114-5. PubMed ID: 18626947
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of exposure to war stress on exacerbations of multiple sclerosis.
    Golan D; Somer E; Dishon S; Cuzin-Disegni L; Miller A
    Ann Neurol; 2008 Aug; 64(2):143-8. PubMed ID: 18570326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The psychosocial effect of multiple sclerosis: the impact of relapses.
    Halper J
    J Neurol Sci; 2007 May; 256 Suppl 1():S34-8. PubMed ID: 17350047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of extracranial venous stenoses in relapsing-remitting multiple sclerosis patients.
    Walker MA
    Mult Scler; 2011 May; 17(5):642; author reply 643-4. PubMed ID: 21421808
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurofunctional correlates of personality traits in relapsing-remitting multiple sclerosis: an fMRI study.
    Gioia MC; Cerasa A; Valentino P; Fera F; Nisticò R; Liguori M; Lanza P; Quattrone A
    Brain Cogn; 2009 Dec; 71(3):320-7. PubMed ID: 19699020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses matter: the costs & consequences of multiple sclerosis relapses.
    Coyle PK; Johnson KP
    J Neurol Sci; 2007 May; 256 Suppl 1():S1-4. PubMed ID: 17350044
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis.
    Kern S; Schrempf W; Schneider H; Schultheiss T; Reichmann H; Ziemssen T
    Mult Scler; 2009 Jun; 15(6):752-8. PubMed ID: 19482864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the natural history of MS: the need for complete data and rigorous definitions.
    Tremlett H; Zhao Y; Devonshire V
    Mult Scler; 2008 Sep; 14(8):1142-3; author reply 1144-7. PubMed ID: 18701573
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis and vitamin D: don't (yet) blame it on the sunshine.
    Stewart G
    Brain; 2009 May; 132(Pt 5):1126-7. PubMed ID: 19372268
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased MS relapse rate during assisted reproduction technique.
    Hellwig K; Beste C; Brune N; Haghikia A; Müller T; Schimrigk S; Gold R
    J Neurol; 2008 Apr; 255(4):592-3. PubMed ID: 18408881
    [No Abstract]   [Full Text] [Related]  

  • 12. Cognitive deficits in multiple sclerosis patients with cerebellar symptoms.
    Valentino P; Cerasa A; Chiriaco C; Nisticò R; Pirritano D; Gioia M; Lanza P; Canino M; Del Giudice F; Gallo O; Condino F; Torchia G; Quattrone A
    Mult Scler; 2009 Jul; 15(7):854-9. PubMed ID: 19542264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis.
    Dineen RA; Vilisaar J; Hlinka J; Bradshaw CM; Morgan PS; Constantinescu CS; Auer DP
    Brain; 2009 Jan; 132(Pt 1):239-49. PubMed ID: 18953055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cognitive evoked potentials in remitting-relapsing and benign forms of multiple sclerosis].
    Vázquez-Marrufo M; González-Rosa J; Vaquero-Casares E; Duque P; Borges M; Izquierdo G
    Rev Neurol; 2009 May 1-15; 48(9):453-8. PubMed ID: 19396761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing-remitting multiple sclerosis.
    Warlop NP; Achten E; Fieremans E; Debruyne J; Vingerhoets G
    Brain Cogn; 2009 Dec; 71(3):410-5. PubMed ID: 19576672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological testing and event-related potentials in the assessment of cognitive performance in the patients with multiple sclerosis--a pilot study.
    Pokryszko-Dragan A; Zagrajek M; Slotwinski K; Gruszka E; Bilinska M; Podemski R
    Clin Neurol Neurosurg; 2009 Jul; 111(6):503-6. PubMed ID: 19233546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.
    Bellmann-Strobl J; Wuerfel J; Aktas O; Dörr J; Wernecke KD; Zipp F; Paul F
    Neurology; 2009 Nov; 73(20):1624-7. PubMed ID: 19917984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Executive function and memory in patients with relapsing-remitting multiple sclerosis.
    Cerezo García M; Martín Plasencia P; Aladro Benito Y; Balseiro Gómez JJ; Rueda Marcos A
    Psicothema; 2009 Aug; 21(3):416-20. PubMed ID: 19622322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No shortcuts to outcome in MS clinical trials?
    Koch-Henriksen N
    Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.